arrow
G

Guido Ghilardi

University of Pennsylvania
H指数:17
被引数:1,537

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells

针对IGHV4-34 b细胞受体的嵌合抗原受体T细胞特异性消除肿瘤性和自身免疫性b细胞

2026-02-040
PRE
CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia

CD19 CAR T细胞疗法在Richter转化中的研究:欧洲慢性淋巴细胞白血病研究倡议进行的 multicentre 回顾性分析

2025-10-220
OAAI
CCR5-targeted allogeneic gamma–delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy

CCR5靶向的异基因γ-δ CD19嵌合抗原受体T细胞用于HIV相关B细胞恶性免疫治疗

2025-10-210
PRE
Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells

基于定向进化的体内再刺激嵌合抗原受体T细胞配体的发现

2025-08-250
OAAI
Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study

广谱抗生素暴露对B细胞淋巴瘤CAR-T治疗效果的影响:一项多中心国际研究

BLOOD
IF23.1
2024-11-050
PRE
Efficacy and Safety of Anti-CDI9 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

抗CDI9和抗BCMA嵌合抗原受体(CAR)T细胞疗法在自身免疫性疾病、淋巴瘤或骨髓瘤患者中的疗效与安全性

BLOOD
IF23.1
2024-11-050
PRE
Clinical Activity of Tisagenlecleucel in Large B Cell Lymphomas According to the 5 th Edition of the Who Classification

根据《世界卫生组织分类》第5版,tisagenlecleucel在大B细胞淋巴瘤中的临床活性

BLOOD
IF23.1
2024-11-050
PRE
EZHI/2 Inhibition Improves the Anti-Tumor Efficacy of CAR and TCR T-Cell Based Therapies Against Multiple Liquid and Solid Tumors

EZHI/2抑制提高了CAR和TCR T细胞为基础疗法对多种液体和实体肿瘤的抗肿瘤疗效

BLOOD
IF23.1
2024-11-050
PRE
CD5 deletion enhances the antitumor activity of adoptive T cell therapies

CD5缺失增强过继性T细胞疗法的抗肿瘤活性

2024-07-195
PRE
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel

苯达莫司汀用于利索卡塔烯前淋巴细胞耗竭的疗效和安全性

2024-04-220
OAAI
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines

苯达莫司汀在axicabtagene ciloleucel之前进行淋巴细胞耗竭是安全的,并且与减少的炎症细胞因子有关

2024-01-268
OAAI
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy

商业CAR T细胞治疗后T细胞淋巴瘤和继发性原发性恶性肿瘤风险

2024-01-2481
PRE
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study

靶向CD19近膜域的新型anti-CD19嵌合抗原受体T细胞产品对非霍奇金淋巴瘤的安全性和有效性: 一项首次人体研究

2023-12-098
OAAI
Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy

调节肠道菌群参与抗原交叉呈递以增强CAR T细胞免疫疗法的抗肿瘤作用

2023-03-0120
OAAI
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy (March, 10.1038/s41591-022-01702-9, 2022)
2022-10-173
OA
Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas
2022-09-0147
OAAI
Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer
2022-07-2944
OA